SARS-CoV-2 Variant Test Breakthrough to Improve Tracking and Understanding of Emerging COVID-19 Mutations

A new highly reliable COVID-19 variant test can accurately identify known SARS-CoV-2 variants and aid in the discovery of novel variants.

Aventus Health (Orlando, FL, USA) has launched its new COVID-19 Variant Test designed to reliably identify known SARS-CoV-2 variants and the discovery of novel variants. Aventus’ COVID-19 Variant Test was developed through an innovative application of its Next-Generation Sequencing (NGS) technology and the cutting-edge, laboratory-developed assay that together break down the sequence of base pairs that constitute the genetic makeup of the various strains of corona virus. The result is a reliable test result that can advance the study, tracking and understanding of emerging COVID-19 variants and their potential impact on public health.


Aventus offers a suite of COVID-19 testing services and will now include reflex testing-to-NGS on all Aventus’ RT-PCR patient tests that return a positive result in order to identify currently known variants as well as those yet to be discovered. There is no additional cost or special instructions for individuals using Aventus’ tests.

According to Aventus’ Medical Director, Michelle Taylor, MD, variant testing is complicated and not widely available because it requires scientists use a process called genomic sequencing, which requires advanced and expensive technology and diagnostic expertise. “The instruments Aventus uses are manufactured for the highest sensitivity genetic sequencing capabilities on the market,” Dr. Taylor noted. “They are critical to our mission of helping healthcare providers leverage innovations in genomics and diagnostics to deliver affordable and effective personalized and precision medicine. Addressing the need for COVID-19 and variant testing and diagnostics is a natural fit for us.”

“This is a breakthrough in healthcare that will greatly aid the general public in better understanding the different strains of COVID-19. It will allow us to know what strain an individual has and even get ahead of the curve on any new strains that may develop,” added Oliver Dawoud, Aventus CEO.


Related Links:
Aventus Health